ABBV
A lymphoma win, with a co-star
AbbVie just got a lift from new data on its epcoritamab combo in newly diagnosed diffuse large B-cell lymphoma, and the headline is pretty simple: the treatment reduced the risk of progression or death. That’s the kind of result that makes investors sit up straighter, because in biotech-land, good trial data can turn a sleepy pipeline into the main event.
Why you should care
This isn’t just about one study reading well in a slide deck. AbbVie has been trying to prove it can keep building beyond its older blockbuster franchises, and oncology is a big part of that plan. A positive progression-free survival result can help strengthen the commercial case for epcoritamab and keep the market focused on the company’s future growth engine instead of just its past hits.
Genmab gets its share of the applause
Genmab is the other name in this story, since the two companies are working on the combo together. For investors, that means this is one of those rare biotech moments where the victory lap has a duet partner. If the data eventually translates into approvals or wider use, both companies could benefit from the upside.
Big picture
Biotech stocks can be fussy little creatures — they’ll sprint on one strong readout and sulk on the next. But when a therapy shows it can meaningfully move the needle in a tough cancer, that’s the sort of thing that can keep the story interesting for a long time.